Cellectar Biosciences, Inc.
Cellectar Biosciences develops drugs for cancer treatment. Its lead candidate, CLR 131, is in Phase 2 studies for B-cell malignancies and other lymphomas. Additional studies include pediatric solid tumors/lymphomas/malignant brain tumors and head and neck cancer. CLR 1900 is a preclinical PDC chemotherapeutic program for solid tumors. The company collaborates with Orano Med and LegoChemBio. Founded in 2002, its headquartered in Florham Park, New Jersey.
Overview
Strengths
- Price to book ratio (1.18) is lower than the sector mean (24.44).
- EV/EBITDA (0.09) is lower than the sector mean (85.60).
- EV/EBIT (0.11) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 0.1 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.3 |